Verition Fund Management
PBLA

Verition Fund Management’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Verition Fund Management’s Portfolio PBLA Stock Details PBLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$1.46K – 2782
2022
Q4 		$1.46K Hold
1
– – ﹤0.01% 2034
2022
Q3 		$5K Buy
+1
New +$21K ﹤0.01% 2946
2022
Q2 		– Sell
-1
Closed -$42K – 3298
2022
Q1 		$42K Hold
1
– – ﹤0.01% 2513
2021
Q4 		$35K Hold
1
– – ﹤0.01% 2451
2021
Q3 		$43K Hold
1
– – ﹤0.01% 1791
2021
Q2 		$57K Hold
1
– – ﹤0.01% 1794
2021
Q1 		$79K Sell
1
-2
-67% -$225K ﹤0.01% 1451
2020
Q4 		$216K Hold
3
– – ﹤0.01% 941
2020
Q3 		$182K Buy
+3
New +$210K ﹤0.01% 951

Other funds holding PBLA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Verition Fund Management's PBLA Position: Q1 2023 in Review

Verition Fund Management sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q1 2023, closing a stake of 1 share — an estimated $1.46K sold.

Verition Fund Management first reported a position in PBLA in Q3 2020 and held it in 9 quarters. The position peaked at $216K in Q4 2020. 15 funds tracked by Wall St. Rank hold PBLA as of Q1 2023.

  • Verition Fund Management reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Verition Fund Management sold 1 Panbela Therapeutics, Inc. Common Stock share in Q1 2023, an estimated $1.46K.
  • Verition Fund Management first reported a position in Panbela Therapeutics, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
  • Verition Fund Management's Panbela Therapeutics, Inc. Common Stock position peaked at $216K in Q4 2020.
  • 15 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Verition Fund Management's 13F filing for Q1 2023, filed 15 May 2023.